vimarsana.com

Latest Breaking News On - Fda approval - Page 4 : vimarsana.com

WOVEN ORTHOPEDICS SECURES SECOND FDA SPINE CLEARANCE - OGMEND® NOW AVAILABLE FOR MOST PEDICLE SCREW DIAMETERS

Iovance Biotherapeutics, Inc (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript February 28, 2024 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]

New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Centinel Spine s lumbar disc replacement implant earns new payer coverage

Centinel Spine earned coverage from a large commercial payer in Tennessee for one- and two-level lumbar disc replacement, the devicemaker said Feb. 21.

It s A First; Cellular Therapy For Melanoma And Drug To Reduce Food Allergic Reactions Get FDA Nod

Latest approvals by the U.S. Food and Drug Administration include Iovance Biotherapeutics Inc.'s Amtagvi - the first cellular therapy indicated for the treatment of unresectable or metastatic melanoma, as well as Genentech's Xolair- the first medication to help reduce allergic reactions to multiple foods after accidental exposure.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.